Diabetes In Control Publisher Steve Freed interviewed Dr. David D’Alessio, Associate Professor of Medicine, Division of Endocrinology, University of Cincinnati, and the Albert Vontz chair in Diabetes Research. Dr. D’Alessio helps us understand some of the newest research on GLP-1’s, how he uses these therapies in his own practice and …
Read More »Why the FDA Said No to First In Class Dapagliflozin
The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 9 to 6 against recommending the approval of the first in class novel antidiabetic agent dapagliflozin, largely because of fears that the product may cause breast and bladder cancer.… The EMDAC panel was also concerned about a lack of pharmacokinetic …
Read More »EASD: Weight Loss with SGLT2 Inhibitors but More Infections
Three possible first in class drugs in the sodium glucose co-transporter (SGLT2 inhibitor) class showed improvements in glycemic control and weight loss, but infections proved troublesome, researchers reported…. Michael Nauck, MD, and colleagues of Diabeteszentrum Bad Lauterberg in Harz, Germany, looked at studies involving three investigational drugs in the sodium …
Read More »Possible New Therapy for Type 2 Diabetes
Inhibitors Of The Novel Target Sodium-dependent Glucose (co-) Transporter (SGLT) For Therapy Of Type 2 Diabetes A plethora of SGLT inhibitors in the patent literature and seven compounds in early clinical development indicate an abundance of interest in the therapeutic use of SGLT inhibitors for the treatment of type 2 …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.